CHMP Issues Positive Opinion on CT-P6 for HER2+ Breast, Gastric Cancers

December 18, 2017 – The European Union’s Committee for Medicinal Products for Human Use (CHMP) has delivered a positive opinion for CT-P6, a trastuzumab biosimilar, for the treatment of patients with HER2-positive early breast cancer, metastatic breast cancer, or metastatic gastric cancer. The CHMP’s opinion will now go to the European Commission (EC) for final review. South Korea-based Celltrion, developer of the monoclonal antibody, announced the CHMP’s … (leggi tutto)